海思科拟与海利克斯共同投资设立子公司

Group 1 - The company plans to jointly invest 97 million yuan to establish a subsidiary named Haishi Biotechnology Co., Ltd., with an investment of 87 million yuan from the company, holding 89.69% equity [1] - Haishi Biotechnology will focus on cutting-edge areas such as ADC (Antibody-Drug Conjugates) and In Vivo CART (Chimeric Antigen Receptor T-cell Therapy) [1] - The company also intends to jointly invest 48.5 million yuan to establish another subsidiary named Haishi Xinyuan Pharmaceutical Technology Co., Ltd., with an investment of 43.5 million yuan from the company, also holding 89.69% equity [1] - Haishi Xinyuan will concentrate on research in new-generation technologies such as small nucleic acid drugs [1] Group 2 - Hailekes is fully owned by the company's controlling shareholder, Wang Junmin [2]